icon-    folder.gif   Conference Reports for NATAP  
  21st Conference on Retroviruses and
Opportunistic Infections
Boston, MA March 3 - 6, 2014
Back grey_arrow_rt.gif
GSK1265744 Demonstrates Robust in Vitro Activity Against Various Clades of HIV-1
  Reported by Jules Levin
CROI 2014 Boston, MA March 3-6
Sharon L Karmon1,2, Hiroshi Mohri2, William Spreen3, Zhi Hong3, David Ho1,2 and Martin Markowitz2
1The Rockefeller University, NY, 2Aaron Diamond AIDS Research Center, NY and 3GlaxoSmithKline, NC, USA
21st Conference on Retroviruses and Opportunistic Infections: Review - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (03/21/14)
HIV Prevention at CROI 2014 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/12/14)
CROI: Monthly GSK744 long-acting injections protect macaques against repeated vaginal SHIV exposures - (03/14/14)
CROI: GSK1265744 Long-Acting Protects Macaques against Repeated High-Dose Intravaginal Challenges & Depo Provera-treated - (03/14/14)
CROI: Long-Acting Integrase Inhibitor GSK744 for PrEP (Once Monthly or maybe longer) - (03/05/14)......"long-acting (LA) antiretroviral formulations requiring infrequent dosing could improve adherence and thus PrEP efficacy.......GSK744 LA has afforded high---level protection against repeated intrarectal SHIV challenges in rhesus macaques......plasma concentrations >3X PAIC90 result in 100% protection.....plasma levels corresponding to protection can be readily achieved in man with quarterly 800mg intramuscular injections.......These data support moving GSK744 LA into clinical evaluation as PrEP in high-risk men who have sex with men - Phase 2 safety and tolerability studies commence in Spring 2014....These data support the evaluation of GSK744 LA as PrEP in other challenge models - Low---dose intravaginal (40LB see link to this CROI webcast below) and high--dose intravaginal (941LB)"